Pricing Log in Create free account

ArriVent BioPharma, Inc. (AVBP) vs DBV Technologies S.A. (DBVT)

ArriVent BioPharma, Inc. and DBV Technologies S.A. are both Biotechnology companies. ArriVent BioPharma, Inc. and DBV Technologies S.A. are of similar size ($615.8M and $603.0M). ArriVent BioPharma, Inc. has the higher net margin (0.00% vs −5,547.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, ArriVent BioPharma, Inc. leads on 9 and DBV Technologies S.A. on 3.

Valuation

Metric AVBP DBVT Biotechnology median
P/E n/m n/m 10.60
P/S n/m 255.21 9.40
P/B 1.77 6.42 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 210.91 9.02
Earnings yield (26.92%) (29.23%) (32.88%)
Free cash flow yield (22.81%) (20.11%) (23.13%)

Profitability

Metric AVBP DBVT Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% (5,571.63%) 0.00%
Net margin 0.00% (5,547.30%) 0.00%
Free cash flow margin 0.00% (5,131.50%) 0.00%
Return on equity (53.10%) (205.75%) (51.96%)
Return on assets (49.30%) (127.19%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AVBP DBVT Biotechnology median
Revenue growth (TTM) — (33.42%) 6.76%
EPS growth (last fiscal year) (68.75%) 10.26% 29.88%
Revenue growth, 5-year CAGR — (12.95%) 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AVBP DBVT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 14.16 3.24 4.97
Net debt to EBITDA 1.73 1.35 1.01

Dividend

Metric AVBP DBVT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AVBP DBVT Biotechnology median
Market cap 603.03m 615.83m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack